New hope for stubborn warts: extended treatment shows promise

NCT ID NCT07457918

Recruiting now Disease control Sponsor: Verrica Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows people who already took part in earlier YCANTH wart studies. It tests whether up to 4 more treatments, applied every 21 days, can safely clear common warts. About 600 adults and children will be monitored for a year. The goal is to see if the medicine continues to work and is safe over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMON WARTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

common wart human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COMMON WARTS COMMON WARTS (VERRUCA VULGARIS) HUMAN PAPILLOMA VIRUS (HPV) WARTS

Contacts and locations

Locations

Florida Center for Dermatology, P.A.
RECRUITING

Saint Augustine, Florida, 32080, United States
Optima Research Boardman
RECRUITING

Boardman, Ohio, 44512, United States
Texas Dermatology
RECRUITING

San Antonio, Texas, 78235, United States
The Indiana Clinical Trials Center, PC
RECRUITING

Plainfield, Indiana, 46168, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.